ENTA (Enanta Pharmaceuticals) Ending Cash Position: $36.78 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTA Enanta Pharmaceuticals Inc ENTA
49 GF Score
Price $14.15
GF Value $7.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Ending Cash Position?

Enanta Pharmaceuticals ENTA +0.50% 49 Ending Cash Position is $36.78 Mil as of Jun. 2026. GuruFocus rates ENTA with a GF Score™ of 49/100 and a GF Value™ of $7.93 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Enanta Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was $36.78 Mil.

Enanta Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2025 ($40.80 Mil) to Mar. 2026 ($38.29 Mil) and declined from Mar. 2026 ($38.29 Mil) to Jun. 2026 ($36.78 Mil).

Enanta Pharmaceuticals's annual Ending Cash Position declined from Sep. 2023 ($89.36 Mil) to Sep. 2024 ($41.20 Mil) and declined from Sep. 2024 ($41.20 Mil) to Sep. 2025 ($35.66 Mil).

Enanta Pharmaceuticals Ending Cash Position Related Terms

Enanta Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Ending Cash Position Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.81 47.96 89.36 41.20 35.66

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.17 35.66 40.80 38.29 36.78
ENTA
49GF Score
Enanta Pharmaceuticals Inc ENTA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Enanta Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Sep. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=41.201+-5.543
=35.66

Enanta Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=38.288+-1.509
=36.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $36.78 Mil mean?
Enanta Pharmaceuticals (ENTA) has a Ending Cash Position of $36.78 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Ending Cash Position too high?
Enanta Pharmaceuticals' current Ending Cash Position is $36.78 Mil. Overall, Enanta Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Ending Cash Position compare to CMPX and CCCC?
Enanta Pharmaceuticals' Ending Cash Position of $36.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Ending Cash Position is $36.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.93, compared to a current price of $14.15 — trading 78.4% above its estimated fair value. The current Ending Cash Position is $36.78 Mil. Enanta Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Ending Cash Position is $36.78 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of $14.15 is trading 78.4% above its estimated GF Value™ of $7.93. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ENTA:

  • Ending Cash Position: $36.78 Mil
  • GF Value™: $7.93 vs. price of $14.15 (78.4% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges 9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
49GF Score

Get the complete analysis for ENTA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.15
Price
$7.93
GF Value